Intrahepatic cholangiocarcinoma affect approximately 2000 people a year in the US. Many patients are not able to have an operation to remove the bile duct cancer. We are preparing to enroll patients in a clinical trial which includes patients who can have an operation and those who cannot. All patients with intrahepatic cholangiocarcinoma confined to the liver and portal nodes will receive 4 cycles of gemcitabine and cisplatinum. Patients who are resectable will undergo an operation. Patients who are not surgical candidates will receive high dose proton therapy to the cancer.